<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00459121</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000539273</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-2006-122</secondary_id>
    <secondary_id>WSU-011807MP2F</secondary_id>
    <secondary_id>WSU-0612004427</secondary_id>
    <secondary_id>ZENECA-IRUSZACT0029</secondary_id>
    <nct_id>NCT00459121</nct_id>
  </id_info>
  <brief_title>Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery</brief_title>
  <official_title>Assessment of Feasibility and Safety of the Addition of ZD6474 (Zactima) to Carboplatin and Paclitaxel Administered Neo-Adjuvantly in Stage IB, II and T3, N1 Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes
      needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy,
      such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells,
      either by killing the cells or by stopping them from dividing. Giving vandetanib together
      with chemotherapy before surgery may make the tumor smaller and reduce the amount of normal
      tissue that needs to be removed.

      PURPOSE: This phase II trial is studying how well giving vandetanib together with carboplatin
      and paclitaxel works in treating patients with stage I, stage II, or stage III non-small cell
      lung cancer that can be removed by surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the feasibility of neoadjuvant vandetanib in combination with carboplatin and
           paclitaxel in patients with resectable stage IB, II, or IIIA non-small cell lung cancer.

      Secondary

        -  Assess the 30-day postoperative mortality rate in these patients.

        -  Assess the toxicity of this regimen in these patients.

        -  Determine the percentage of patients who complete all planned courses of therapy.

        -  Assess the clinical response rate in patients treated with this regimen.

        -  Assess the pathologic complete response rate in patients treated with this regimen.

      OUTLINE: This is a multicenter study.

      Patients receive oral vandetanib once daily on days 1-21. Patients also receive paclitaxel IV
      over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 3 weeks for up
      to 3 courses.

      Patients undergo surgery at least 3 weeks after the last course of chemotherapy.

      PROJECTED ACCRUAL: A total of 15 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Resection (R0) Rate</measure>
    <time_frame>Following three cycles of pre-operative zactima and carboplatin/paclitaxel</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-Operative Mortality Rate</measure>
    <time_frame>at 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Toxicity of This Regimen and the Percentage of Patients Completing All Planned Cycles of Therapy</measure>
    <time_frame>Weekly for the first cycle; Thereafter within 72 hours of each dose of carboplatin/paclitaxel</time_frame>
    <description>Serum chemistry includes Albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium, chloride, creatinine, glucose, potassium, total protein, SGOT [AST], SGPT [ALT], sodium, laboratory tests should be done on a weekly basis for the first cycle. After the first cycle laboratory tests should be done within 72 hours of each dose of carboplatin/paclitaxel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the Clinical Response Rate of the Proposed Pre-operative Regimen</measure>
    <time_frame>End of three cycles of treatment</time_frame>
    <description>Patients will undergo tumor evaluation when all of the three cycles have been completed unless the treating physician has concerns regarding tumor progression. If the patient has undergone tumor evaluation prior to the last cycle the patient will require repeat tumor assessment within 4 weeks of completion of the last cycle of therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the Complete Pathologic Complete Response (CR) Rate With This Regimen.</measure>
    <time_frame>30 days post surgery</time_frame>
    <description>Evaluation of the number of patients who have no evidence of tumor in the resected tumor.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Zactima, Paclitaxel, Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zactima- 100 mg orally daily, starting on day 1 of cycle 1. Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1. Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1 Duration of each cycle: 21 days. The last dose of zactima will be on the first day of the last cycle.
Neoadjuvant Surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1</description>
    <arm_group_label>Zactima, Paclitaxel, Carboplatin</arm_group_label>
    <other_name>Paraplatin ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1.</description>
    <arm_group_label>Zactima, Paclitaxel, Carboplatin</arm_group_label>
    <other_name>Taxol ®</other_name>
    <other_name>Onxal TM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zactima</intervention_name>
    <description>Zactima- 100 mg orally daily, starting on day 1 of cycle 1.</description>
    <arm_group_label>Zactima, Paclitaxel, Carboplatin</arm_group_label>
    <other_name>Caprelsa</other_name>
    <other_name>ZD6474</other_name>
    <other_name>Vandetanib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
    <description>Neoadjuvant surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment.</description>
    <arm_group_label>Zactima, Paclitaxel, Carboplatin</arm_group_label>
    <other_name>R0 Resection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed non-small cell lung cancer (NSCLC), meeting
             1 of the following staging criteria:

               -  Stage IB or II disease

               -  T3, N0-1 disease (stage IIIA)

          -  Deemed a surgical candidate

          -  No prior lung cancer (NSCLC or small cell lung cancer)

        PATIENT CHARACTERISTICS:

          -  ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%

          -  WBC ≥ 3,000/mm³

          -  Absolute neutrophil count ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Bilirubin normal

          -  AST and ALT ≤ 2.5 times upper limit of normal (ULN)

          -  Creatinine ≤ 1.5 times ULN

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No evidence of severe or uncontrolled systemic disease or any concurrent condition
             that, in the opinion of the investigator, would preclude study compliance

          -  No peripheral neuropathy ≥ grade 2

          -  No hemoptysis within the past 12 weeks

          -  No spontaneous bleeding within the past 12 weeks

          -  No clinically significant cardiac event (e.g., NYHA class II-IV heart disease,
             myocardial infarction) within the past 3 months

          -  No history of asymptomatic sustained ventricular tachycardia or arrhythmia that is
             symptomatic or requires treatment, including any of the following:

               -  Multifocal premature ventricular contractions

               -  Bigeminy

               -  Trigeminy

               -  Ventricular tachycardia

               -  Uncontrolled atrial fibrillation

                    -  Atrial fibrillation controlled with medication allowed

          -  No history of QTc prolongation as a result from other medication that required
             discontinuation of that medication

          -  No congenital long QT syndrome or first-degree family relative with an unexplained
             death before the age of 40

          -  No left bundle branch block

          -  No QTc with Bazett's correction that is unmeasurable or QTc ≥ 480 milliseconds on
             screening ECG

               -  Patients with QTc ≥ 480 milliseconds on screening ECG may have ECG repeated twice

                    -  Average QTc from the 3 screening ECG's must be &lt; 480 milliseconds

          -  No uncontrolled hypertension (systolic BP &gt; 160 mm Hg or diastolic BP &gt; 100 mm Hg)

          -  No active diarrhea or active gastrointestinal disease that may affect the absorption
             of study drugs or ability to tolerate study drugs

          -  No other malignancy within the past 3 years except in situ cervical carcinoma or
             adequately treated basal cell or squamous cell carcinoma of the skin

        PRIOR CONCURRENT THERAPY:

          -  More than 4 weeks since major surgery and recovered

          -  No prior carboplatin, paclitaxel, or vandetanib

          -  More than 30 days since prior investigational agents

          -  More than 2 weeks since prior and no concurrent drugs that induce CYP3A4 including,
             but not limited to, any of the following:

               -  Rifampin

               -  Phenytoin

               -  Carbamazepine

               -  Barbiturates

               -  Hypericum perforatum (St. John's wort)

          -  No medication that may cause QTc prolongation or induce torsades de pointes for 2
             weeks prior to beginning study treatment, during, and for 2 weeks after completion of
             study treatment

          -  No concurrent combination antiretroviral treatment for HIV-positive patients

          -  No other concurrent investigational agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shirish M. Gadgeel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2007</study_first_submitted>
  <study_first_submitted_qc>April 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2007</study_first_posted>
  <results_first_submitted>November 12, 2012</results_first_submitted>
  <results_first_submitted_qc>November 12, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 7, 2012</results_first_posted>
  <last_update_submitted>November 15, 2017</last_update_submitted>
  <last_update_submitted_qc>November 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barbara Ann Karmanos Cancer Institute</investigator_affiliation>
    <investigator_full_name>Shirish M. Gadgeel</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>stage I non-small cell lung cancer</keyword>
  <keyword>stage II non-small cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Unable to enroll patients in a timely fashion. The decision was made to close the study after consulting with AstraZeneca.</recruitment_details>
      <pre_assignment_details>Feasibility and safety.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Zactima, Paclitaxel, Carboplatin</title>
          <description>Zactima- 100 mg orally daily, starting on day 1 of cycle 1. Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1. Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1 Duration of each cycle: 21 days. The last dose of zactima will be on the first day of the last cycle.
Neoadjuvant Surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zactima, Paclitaxel, Carboplatin</title>
          <description>Zactima- 100 mg orally daily, starting on day 1 of cycle 1. Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1. Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1 Duration of each cycle: 21 days. The last dose of zactima will be on the first day of the last cycle.
Neoadjuvant Surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.5" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Resection (R0) Rate</title>
        <time_frame>Following three cycles of pre-operative zactima and carboplatin/paclitaxel</time_frame>
        <population>No analysis will be completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Zactima+Carboplatin &amp; Paclitaxel-assess Feasibility &amp; Safety</title>
            <description>Study closed before an evaluable number of participants could be accrued. No summary of statistics will be collected for two participants, per the statistician.</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Resection (R0) Rate</title>
          <population>No analysis will be completed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-Operative Mortality Rate</title>
        <time_frame>at 30 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess Toxicity of This Regimen and the Percentage of Patients Completing All Planned Cycles of Therapy</title>
        <description>Serum chemistry includes Albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium, chloride, creatinine, glucose, potassium, total protein, SGOT [AST], SGPT [ALT], sodium, laboratory tests should be done on a weekly basis for the first cycle. After the first cycle laboratory tests should be done within 72 hours of each dose of carboplatin/paclitaxel.</description>
        <time_frame>Weekly for the first cycle; Thereafter within 72 hours of each dose of carboplatin/paclitaxel</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess the Clinical Response Rate of the Proposed Pre-operative Regimen</title>
        <description>Patients will undergo tumor evaluation when all of the three cycles have been completed unless the treating physician has concerns regarding tumor progression. If the patient has undergone tumor evaluation prior to the last cycle the patient will require repeat tumor assessment within 4 weeks of completion of the last cycle of therapy</description>
        <time_frame>End of three cycles of treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess the Complete Pathologic Complete Response (CR) Rate With This Regimen.</title>
        <description>Evaluation of the number of patients who have no evidence of tumor in the resected tumor.</description>
        <time_frame>30 days post surgery</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Zactima+Carboplatin &amp; Paclitaxel-assess Feasibility &amp; Safety</title>
          <description>Study closed before an evaluable number of participants could be accrued. No summary of statistics will be collected for two participants, per the statistician.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased ANC</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Decreased WBC count</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Decreased hemoglobin</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Bicarbonate</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was a single center study. We did not accrue enough particpants in a timely fashion and a joint decision was made with AstraZeneca to terminate the study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Shirish Gadgeel, M.D.</name_or_title>
      <organization>Barbara Ann Karmanos Cancer Institute</organization>
      <phone>313-576-8753</phone>
      <email>sgadgeel@med.umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

